echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: Oral JAK inhibitor abroctinib for moderate to severe atopic dermatitis

    NEJM: Oral JAK inhibitor abroctinib for moderate to severe atopic dermatitis

    • Last Update: 2021-03-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab for the treatment of atopic dermatitis.
    Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab.
    Clinical effect of treatment of atopic dermatitis 48.
    4% of patients in the 200 mg abrocitinib group, 36.
    6% of the 100 mg abrocitinib group, 36.
    5% of the dupilumab group, and 14.
    0% of the placebo group had an IGA response at week 12; EASI at week 12 -75 response rates were 70.
    3%, 58.
    7%, 58.
    1% and 27.
    1%.
    48.
    4% of the 200mg abrocitinib group, 36.
    6% of the 100mg abrocitinib group, 36.
    5% of the dupilumab group, and 14.
    0% of the placebo group had an IGA response at week 12; the EASI-75 response rate at week 12 was 70.
    3%, respectively , 58.
    7%, 58.
    1% and 27.
    1%.
    Compared with placebo, abrocitinib can significantly improve the signs and symptoms of moderate to severe atopic dermatitis.
    In improving the itching response, the effect of 200mg abroctinib group is better than dupilumab.
    Compared with placebo, abrocitinib can significantly improve moderate to severe atopic dermatitis.
    The signs and symptoms of the 200mg abroctinib group are better than dupilumab in improving the itching response.
    Original Source: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.